EARNINGS (LOSS) PER SHARE

6 Months Ended

Jun. 30, 2023

Earnings (loss) per share attributable to Bausch Health Companies Inc. is calculated as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
(in millions, except per share amounts)	2023		2022		2023		2022
Net income (loss) attributable to Bausch Health Companies Inc.	$	26	$	(145)	$	(175)	$	(214)
Basic weighted-average common shares outstanding	364.8		362.2		364.1		361.5
Diluted effect of stock options and RSUs	2.3		—		—		—
Diluted weighted-average common shares outstanding	$	367.1	$	362.2	$	364.1	$	361.5
Earnings (loss) per share attributable to Bausch Health Companies Inc.

Basic	$	0.07	$	(0.40)	$	(0.48)	$	(0.59)
Diluted	$	0.07	$	(0.40)	$	(0.48)	$	(0.59)

During the six months ended June 30, 2023 and during the three and six months ended June 30, 2022, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 1,184,000 common shares for the three months ended June 30, 2022, and approximately 2,859,000 and 2,392,000 common shares for the six months ended June 30, 2023 and 2022, respectively.

During the three and six months ended June 30, 2023, time-based RSUs, performance-based RSUs and stock options to purchase approximately 16,308,000 and 17,613,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.

During the three and six months ended June 30, 2022, time-based RSUs, performance-based RSUs and stock options to purchase approximately 15,372,000 and 13,771,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.

During each of the three and six months ended June 30, 2023, an additional 90,000, performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.

During the three months ended June 30, 2022, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.